Merck & Company, Inc. · NYSE:MRK

Merck & — Goldman Sachs Alzheimer's Symposium 2016

25 slides from Merck &'s conference presentation, Apr 11, 2016

  1. Slide 1: Amyloid, BACE and Beyond: Alzheimer's Disease Research at Merck

    Amyloid, BACE and Beyond: Alzheimer’s Disease Research at Merck David Michelson, M.D., VP, Clinical Neuroscience Research Goldman Sachs Alzheimer’s Symposium April 11, 2016

  2. Slide 2: Forward-Looking Statement of Merck & Co., Inc.

    FORWARD-LOOKING STATEMENT OF MERCK & CO., INC., KENILWORTH, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995

  3. Slide 3: Merck's BACE Inhibitor: Verubecestat (MK-8931)

    Merck’s BACE Inhibitor: Verubecestat (MK-8931)

  4. Slide 4: The Amyloid Pathway

    The Amyloid Pathway Senile plaque Aβ aggregation/oligomerization Neuron Death sAPPα sAPPβ APP BACE Soluble Aβ α-Secretase Cleavage γ-Secretase Extracellular Cell membrane Intracellular C83 C99 AICD 4 Adapted from Gandy, 2005

  5. Slide 5: MK-8931 Reduces Aβ in CSF: A Multiple Dose CSF Study in AD Patients

    MK-8931 Reduces Aβ in CSF: A Multiple Dose CSF Study in AD Patients Aβ40MK 8931 40 mg (N 8 Planned) sAPPβ MK-8931 40 mg (N=8 Planned) 160 160 CSF sAppβ % of Baseline CSF Aβ40 % of Baseline 120 120 100 100 80 80 40 40 0 0 Baseline 0 4 8 12 16 20 24 28 32 36 Baseline 0 4 8 12 16 20 24 28 32 36 Day -1

  6. Slide 6: MK-8931 PK/PD For Dose Selection

    MK-8931 PK/PD For Dose Selection • Objective: test maximally and sub-maximally Aβ lowering doses • Steady-state dose-response predicted from CSF with 90% confidence intervals – >50% CSF Aβ reduction at 12 mg once daily – >75% reduction at doses 40 mg once daily – 60 mg daily dose in vanguard cohort

  7. Slide 7: Pivotal Study Design Considerations

    Pivotal Study Design Considerations • Disease Severity – Safety – Methodology needs and availability • Diagnostic – Imaging/CSF for symptomatic patients • Regulatory 7

  8. Slide 8: P017: Mild-Moderate AD Trial Design

    P017: Mild-Moderate AD Trial Design • Randomized, placebo controlled, parallel-group, double blind trial • 18 month duration of treatment • MMSE 15-26 at study entry • Two co-primaries: cognition (ADAS-Cog) and function (ADCS-ADL) • Seamless phase 2/3 design with initial vanguard cohort MK-8931 60 m

  9. Slide 9: P017: Mild-Moderate AD Trial Design

    P017: Mild-Moderate AD Trial Design • Randomized, placebo controlled, parallel-group, double blind trial • 18 month duration of treatment • MMSE 15-26 at study entry • Two co-primaries: cognition (ADAS-Cog) and function (ADCS-ADL) • Seamless phase 2/3 design including initial vanguard cohort MK-8931

  10. Slide 10: P019: Prodromal Study

    P019: Prodromal Study • Randomized, placebo controlled, parallel-group, double blind trial • 24 month duration of treatment • Subjects must have: – MMSE ≥ 24 – Threshold impairment on neuropsychological testing – Positive PET scan for amyloid • Primary outcome measure: CDR-SB MK-8931 40 mg MK-8931 1

  11. Slide 11: Mild-Moderate Alzheimer's Disease: Too Late for BACE Inhibition?

    Mild-Moderate Alzheimer’s Disease: Too Late for BACE Inhibition?

  12. Slide 12: Mild-Moderate Initially, Then Prodromal

    Mild-Moderate Initially, Then Prodromal • Considerations that drove the decision to conduct protocol 17 in individuals with mild-moderate Alzheimer’s Disease – Medical need – Balancing benefit and risk for a novel mechanism vs. target population risk for disease progression – Appropriate and establi

  13. Slide 13: Mild-Moderate Initially, Then Prodromal

    Mild-Moderate Initially, Then Prodromal • Considerations that drove the decision to conduct protocol 17 in individuals with mild-moderate Alzheimer’s Disease – Medical need – Balancing benefit and risk for a novel mechanism vs. target population risk for disease progression – Appropriate and establi

  14. Slide 14: Mild-Moderate Initially, Then Prodromal

    Mild-Moderate Initially, Then Prodromal • Considerations that drove the decision to conduct protocol 17 in individuals with mild-moderate Alzheimer’s Disease – Medical need – Balancing benefit and risk for a novel mechanism vs. target population risk for disease progression – Appropriate and establi

  15. Slide 15: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum 15

  16. Slide 16: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum – The impact of intervening successfully will be greater earlier than later...but 16

  17. Slide 17: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum – The impact of intervening successfully will be greater earlier than later...but – The differences between early and late intervention may be more in degree than in kind 17

  18. Slide 18: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum – The impact of intervening successfully will be greater earlier than later...but – The differences between early and late intervention may be more in degree than in kind Intervention while presymptom

  19. Slide 19: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum – The impact of intervening successfully will be greater earlier than later...but – The differences between early and late intervention may be more in degree than in kind Intervention while presymptom

  20. Slide 20: A Tentative Conclusion (While Awaiting Data)

    A Tentative Conclusion (While Awaiting Data) • Alzheimer’s is a continuum along a severity spectrum – The impact of intervening successfully will be greater earlier than later...but – The differences between early and late intervention may be more in degree than in kind Intervention while presymptom

  21. Slide 21: Beyond Amyloid: Next Generation Programs

    Beyond Amyloid: Next Generation Programs

  22. Slide 22: Alzheimer's Therapeutics: Medical Need

    Alzheimer’s Therapeutics: Medical Need • For the foreseeable future there will be an ongoing need for a triad of better interventions Slow/Halt Progression Control Neuropsychiatric Alzheimer’s Improve Function Signs and Symptoms Disease 22

  23. Slide 23: New Clinical Development Programs

    New Clinical Development Programs Amyloid Targeted: BACE inhibition Slow/Halt Progression Tau targeted: Inhibit aggregation 23

  24. Slide 24: New Clinical Development Programs

    New Clinical Development Programs Amyloid Targeted: BACE inhibition Slow/Halt Progression Tau targeted: Inhibit aggregation Novel cholinergic and non-cholinergic Improve Function targets to improve cognitive function 24

  25. Slide 25: New Clinical Development Programs

    New Clinical Development Programs Amyloid Targeted: BACE inhibition Slow/Halt Progression Tau targeted: Inhibit aggregation Novel cholinergic and non-cholinergic Improve Function targets to improve cognitive function Neuropsychiatric Sleep, agitation/psychosis Signs and Symptoms 25

Merck & — Goldman Sachs Alzheimer's Symposium 2016 on 6ix